DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 17:47:01 29/05/2024 BST | ||
| 0.67 EUR / 0.73 EUR | -1.41% |
|
| Current month | +7.58% | ||
| 1 month | +47.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 0.68 | -4.23% |
| 28/05/24 | 0.71 | 0.00% |
| 27/05/24 | 0.71 | -6.58% |
| 24/05/24 | 0.76 | +1.33% |
| 23/05/24 | 0.75 | -6.25% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 04:38 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D84 |
| ISIN | DE000MG0D847 |
| Date issued | 18/03/2024 |
| Strike | 375 $ |
| Maturity | 20/12/2024 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 1.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.5 € |
|---|---|
| Lowest since issue | 0.46 € |
| Spread | 0.06 € |
| Spread % | 8.22% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
223.3
USD
Average target price
363.9
USD
Spread / Average Target
+62.95%
- Stock Market
- Certificates
- Certificat
